French drugmaker Sanofi has halted the development of its antibody-drug conjugate (ADC) tusamitamab ravtansine after the drug failed a phase 3 trial in non-small cell lung cancer (NSCLC). The drug, ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
Subscribe now to view details for this work, and gain access to over 18 million auction results. Purchase One-Day Pass ...
The WhatPackaging? team visited the stall and spoke to the Pune-based manufacturer about the coating. Over a decade, the IndiaCorr Expo and India Folding Carton has proved to be a solid platform for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results